The phrase “most serious recall class” does real work on a worried patient, and it is worth slowing down to say what this one is and is not. On May 8, 2026 the FDA designated Boston Scientific’s Accolade-family pacemaker action a Class I recall (AHA News). Per the openFDA device enforcement record (Z-1770-2026), the firm’s own remedy, distributed as an Urgent Medical Device Correction on March 19, 2026, is a software maintenance release — SMR6 — not a device retrieval. The companion record (Z-1771-2026) covers the CRT-P devices; the two together reach 718,456 and 685,776 units, the basis for the roughly 1.4 million figure.

The clinical signal is real but bounded. The Heart Rhythm Society notice attributes four deaths to high battery impedance driving devices into Safety Mode: three patients had syncope requiring hospitalization and later died, and one died after a replacement procedure. That last detail matters. Replacement is not a free action; it carries its own procedural risk, which is precisely why the advisory states that “prophylactic replacement before confirmation of high battery impedance is not recommended for Accolade devices under advisory.”

A Class I label describes the worst plausible outcome, not the expected one — and here the manufacturer’s own guidance is to confirm before you cut.

So the measured reading is this: identify your affected patients, apply the software update, and intensify monitoring for those who are pacing-dependent or within roughly three years of expected battery life, as HRS advises. Remote-monitored patients need no schedule change.

What is not yet settled deserves equal emphasis. A widely cited figure of 2,557 serious injuries appears in secondary trade coverage; the lead’s own source notes the FDA correction page returned a 404 on automated retrieval, so I would treat that injury count as unconfirmed at the primary level pending the indexed FDA record. We also do not know, from these sources, the population denominator — how many of the 1.4 million implants will actually develop high impedance, or over what interval. A recall class is a regulatory severity tier, not an event rate.

This is analysis, not medical advice; affected patients should follow their own cardiology team. AI-drafted under the direction of Armando Cuesta, MD.